| Company/Division name | Orca Bio |
| Parent company | Orca Bio |
| Type of work | Manufacturing |
| Reshoring category: | Reshoring |
| Total number of jobs (added or to be added): | 200 |
| Year reshoring announced: | 2025 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 192 |
| State(s) reshored to: | CA |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | T-cell immunotherapy |
| What domestic positive factors made reshoring more attractive? | Eco-system synergies, Higher productivity, Manufacturing/engineering joint innovation (R&D) |
